Interaction of nicotine and a H2-receptor antagonist, famotidine, on gastrin and chromogranin A expression.
The purpose of this study is to examine the effect of nicotine on famotidine-induced hypergastrinemia in the rat. In addition, the effects of nicotine on gene expression for gastrin and chromogranin A (CGA) in the stomach were examined. Famotidine treatment alone (20 mg/kg. 2 x/day for 14 days) increased serum gastrin levels significantly (P < 0.05) but not antral levels of gastrin mRNA and peptide. Nicotine treatment (12 mg/kg/d) alone did not affect serum gastrin levels; however, nicotine potentiated the hypergastrinemic action of famotidine. The hypergastrinemic action of nicotine was not mediated by a downregulation of stomach somatostatin (SRIF) since stomach SRIF mRNA levels were unaffected by nicotine treatment. Administration of nicotine and famotidine also upregulated stomach CGA gene expression (i.e., mRNA and protein levels) significantly.
Gomez
G
G
Department of Surgery, University of Texas Medical Branch, Galveston 77555-0725, USA.
Udupi
V
V
Greeley
G H
GH
D000818:Animals; D053379:Chromogranin A; D002864:Chromogranins / Q000235:genetics* / Q000378:metabolism; D015738:Famotidine / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000378:metabolism; D005755:Gastrins / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D008297:Male; D009538:Nicotine / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013004:Somatostatin / Q000235:genetics / Q000378:metabolism; D013270:Stomach / Q000187:drug effects*
D053379:Chromogranin A; D002864:Chromogranins; D005755:Gastrins; D006635:Histamine H2 Antagonists; D012333:RNA, Messenger; C506153:chromogranin A, rat; D013004:Somatostatin; D015738:Famotidine; D009538:Nicotine